Summary
A mid-size, top 5 European pharmaceutical company engaged PRA in a global Phase III study in 20 countries on patients with advanced breast cancer previously treated with or resistant to airmaximus an anthracycline and who are taxane resistant. By identifying optimal sites in in Russia, Ukraine, Belarus, and Estonia, PRA recruited 318 patients at 25 sites, compared to 450+ patients at 150 sites in Rest of World (ROW).
Register to download
Optimal Recruitment Strategies
You may also be interested in:
Blog
Kids with Cancer: A Survivor Shares Her Story
Read Story
Blog
Lighting the Night to Fight Cancer
Every year, more than 60,000 people are diagnosed with leukemia, and more than 382,000 live with the disease or are in remission.
Read Story
Blog
Gilda's Club: Support Community for Cancer Patients
Read Story
View all related content and resources for Oncology
Explore Insights